Phase I/IB Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab BGB-A317 in Patients with Unresectable Locally Advanced or Metastatic Solid Tumors

Brief Summary

Type:
Lung Cancers

Study Type:
Treatment

Phase:
I

ClinicalTrials.gov Identifier:
NCT04047862

Study #:
STUDY00146805

Start Date:
Dec 19, 2021

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04047862

View Complete Trial Details & Eligibility at ClinicalTrials.gov